BIOGEN INC.

BIIBSEC EDGAR

Biological Products, (No Diagnostic Substances)(DE)CIK: 875045

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenues	$9.8B	$10.2B	$11.0B	$13.4B	$14.4B
Cost of Goods and Services Sold	$2.5B	$2.3B	$2.1B	$1.8B	$2.0B
Gross Profit	—	—	—	—	—
Research and Development Expense	—	—	—	—	—
Selling, General and Administrative Expense	$2.5B	$2.4B	$2.7B	$2.5B	$2.4B
Operating Income (Loss)	—	—	—	—	$7.0B
Interest Expense	$246.9M	$246.6M	$253.6M	$222.5M	$187.4M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$28.0B	$26.8B	$24.6B	$23.9B	$24.6B
Assets, Current	$7.5B	$6.9B	$9.8B	$7.9B	$6.9B
Cash and Cash Equivalents, at Carrying Value	—	—	—	—	—
Accounts Receivable, after Allowance for Credit Loss, Current	$1.4B	$1.7B	$1.7B	$1.5B	$1.9B
Inventory, Net	$2.5B	$2.5B	$1.3B	$1.4B	$1.1B
Liabilities	$11.3B	$12.0B	$11.2B	$12.9B	$13.9B
Liabilities, Current	$5.5B	$3.4B	$3.3B	$4.3B	$3.7B

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	$1.5B	$1.4B	$3.6B	$4.2B	$7.1B
Net Cash Provided by (Used in) Investing Activities	-$4.1B	$1.6B	-$563.7M	-$608.6M	$470.5M
Net Cash Provided by (Used in) Financing Activities	$149.3M	-$1.7B	-$2.1B	-$5.3B	-$5.9B
Payments to Acquire Property, Plant, and Equipment	$277.0M	$240.3M	$258.1M	$424.8M	$514.5M
Payments for Repurchase of Common Stock	—	$750.0M	$1.8B	$6.7B	$5.9B

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)